imatinib has been researched along with Leucocythaemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, D | 1 |
| Zhang, Z | 1 |
| Lu, X | 1 |
| Feng, Y | 1 |
| Luo, K | 1 |
| Gan, J | 1 |
| Yingxue, L | 1 |
| Wan, J | 1 |
| Li, X | 2 |
| Zhang, F | 1 |
| Tu, Z | 1 |
| Cai, Q | 1 |
| Ren, X | 1 |
| Ding, K | 1 |
| Radi, M | 1 |
| Dreassi, E | 1 |
| Brullo, C | 1 |
| Crespan, E | 1 |
| Tintori, C | 1 |
| Bernardo, V | 1 |
| Valoti, M | 1 |
| Zamperini, C | 1 |
| Daigl, H | 1 |
| Musumeci, F | 1 |
| Carraro, F | 1 |
| Naldini, A | 1 |
| Filippi, I | 1 |
| Maga, G | 1 |
| Schenone, S | 1 |
| Botta, M | 1 |
| Wang, Q | 1 |
| Liu, F | 1 |
| Qi, S | 1 |
| Qi, Z | 1 |
| Yan, XE | 1 |
| Wang, B | 1 |
| Wang, A | 1 |
| Wang, W | 2 |
| Chen, C | 1 |
| Liu, X | 1 |
| Jiang, Z | 1 |
| Hu, Z | 1 |
| Wang, L | 1 |
| Ren, T | 1 |
| Zhang, S | 1 |
| Yun, CH | 1 |
| Liu, Q | 1 |
| Liu, J | 1 |
| Gu, X | 1 |
| Guan, M | 1 |
| Jiang, C | 1 |
| Song, Q | 1 |
| Sun, N | 1 |
| Zou, Y | 1 |
| Zhou, Q | 1 |
| Chen, J | 1 |
| Qiu, J | 1 |
4 other studies available for imatinib and Leucocythaemia
| Article | Year |
|---|---|
Hybrid compounds as new Bcr/Abl inhibitors.
Topics: Cell Line, Tumor; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Leukemia; Mode | 2011 |
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Leu | 2011 |
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Dose-Respons | 2018 |
Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Prol | 2020 |